City Center Advisors LLC Acquires Shares of 9,400 Kenvue Inc. (NYSE:KVUE)

City Center Advisors LLC acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 9,400 shares of the company’s stock, valued at approximately $217,000.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Kenvue by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after acquiring an additional 17,908,497 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after purchasing an additional 25,238,112 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Kenvue by 9.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock valued at $1,451,927,000 after purchasing an additional 7,023,047 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Kenvue by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock valued at $1,647,087,000 after purchasing an additional 4,815,126 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Kenvue by 11.1% during the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock valued at $1,466,147,000 after purchasing an additional 6,825,611 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 0.6 %

NYSE:KVUE opened at $21.85 on Wednesday. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.55. The company has a market cap of $41.84 billion, a PE ratio of 28.01, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a 50 day simple moving average of $21.97 and a two-hundred day simple moving average of $20.17.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The firm’s revenue was down .3% on a year-over-year basis. Research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is 105.13%.

Analysts Set New Price Targets

KVUE has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Piper Sandler lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. Finally, Citigroup decreased their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.10.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.